Delcath Systems, Inc. (DCTH) Stock Price & How to Invest

Last updated November 2026

Short answer

Delcath Systems (DCTH) is a small-cap oncology company that sells HEPZATO KIT, an FDA-approved system that floods the liver with high-dose melphalan while filtering it out of the blood, for uveal melanoma that has spread to the liver. On November 20, 2026 the shares closed near $18.78, up about 89% year to date, for a market cap of roughly $653 million, against about $110 million of trailing revenue and a debt-free balance sheet holding about $104 million in cash and investments.

DCTH stock price

As of 2026-11-20, Delcath Systems, Inc. (DCTH) last closed at $18.79, up 109.7% over the past year. Over the past 52 weeks it has traded between $8.60 and $21.77.

DCTH last close
$18.79
1 day
-2.34%
1 month
+27.82%
1 year
+109.71%
52-week range
$8.60 to $21.77
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Delcath Systems, Inc.'s investor relations page. Walnut is informational, not investment advice.

DCTH key stats

At $18.79 on November 20, 2026, Delcath Systems, Inc. (DCTH) has a market cap of $654M and a P/E of 117.5 on trailing earnings (69.0 on forward earnings).

Market cap
$654M
P/E (trailing)
117.5
P/E (forward)
69.0
EPS (trailing 12 months)
$0.16
Price to book
4.9
Beta
0.60

Market cap, P/E and yield are measured at the $18.79 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Delcath Systems, Inc. (DCTH)?

The last two weeks for Delcath Systems, Inc., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • DCTH closed at $18.79 on November 20, 2026, down 8.6% over the past five trading days (from $20.55).
  • On November 12, 2026, BTIG kept its Buy rating and $25.00 target.
  • On November 10, 2026, HC Wainwright & Co. raised its target to $36.00 from $32.00 (Buy).
  • On November 9, 2026, BTIG raised its target to $25.00 from $21.00 (Buy).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Delcath Systems, Inc. (DCTH) do?

Delcath Systems, based in New York, develops and sells percutaneous hepatic perfusion (PHP), a procedure that isolates the liver's blood supply, delivers a high dose of the chemotherapy drug melphalan directly to it, and runs the returning blood through filters before it re-enters the body. In the US the product is sold as HEPZATO KIT, approved by the FDA in August 2023 for adults with uveal melanoma (a rare eye cancer) that has spread to the liver and cannot be removed surgically. In Europe the same filtration device is sold as CHEMOSAT. Each HEPZATO treatment is a hospital procedure performed by an interventional radiology and surgical oncology team, so growth depends on how many cancer centers are trained and actively treating patients.

The latest quarter was the strongest in the company's history. Revenue for the September 2026 quarter was about $35.1 million, up from about $20.6 million a year earlier, with HEPZATO KIT contributing about $32.7 million and CHEMOSAT about $2.4 million. Gross margin was about 89%, net income was about $7.0 million ($0.17 per diluted share), and adjusted EBITDA was about $11.5 million. HEPZATO volume rose about 72% year over year and the company reported 33 active treatment centers, up from 28 at the end of 2025. Management raised 2026 revenue guidance to $115 million to $117 million, after starting the year at a floor of $100 million and lifting it to $104 million to $108 million in August.

The investment picture is a commercial-stage story with a clinical-stage option attached. Delcath has no debt, about $104 million in cash and short-term investments, positive operating cash flow, and a $25 million share buyback (about $16 million left at September 30). The stock has been volatile: it fell sharply in late 2025 when the company cut guidance after a slower quarter, traded near $8 at its lows, and recovered to about $14 by early November 2026 before jumping to about $18.50 after the November 9 third-quarter report. It closed at about $18.78 on November 20, 2026, up about 89% year to date and about 129% over one year, and about 30% over the past month. The open questions are how large the US uveal melanoma market can get, how concentrated sales are among a few hospitals, and whether trials in colorectal and breast cancer liver metastases widen the addressable market several times over.

What's driving Delcath Systems, Inc. (DCTH)?

1. More treatment centers and more patients per center

HEPZATO sales are a function of active sites and procedure volume. Delcath ended 2025 with 28 active centers and reported 33 at the end of September 2026, while procedure volume rose about 72% year over year in the third quarter. Full-year 2026 guidance now assumes HEPZATO volume growth of at least 41% over 2025, up from the 20% assumption in the February outlook. Each new center needs a trained team, hospital formulary approval and a referral flow from ocular oncologists, so onboarding takes months. Growth past the current base depends on new centers ramping and on patients receiving more of the up to six treatments the label allows. Slower volume was the weak spot in late 2025.

2. Profitability and cash generation

Delcath turned profitable in 2025 for the first time in its long history, posting full-year net income of about $2.7 million and adjusted EBITDA of about $25.1 million on $85.2 million of revenue. In 2026 the margin picture improved: nine-month net income was about $8.6 million, third-quarter gross margin was about 89%, and quarterly operating cash flow was about $8.2 million. Operating expenses are rising, with third-quarter R&D at about $11.0 million and SG&A at about $13.1 million, because the company is funding three randomized trials from its own cash. The $25 million buyback authorized in November 2025 had retired about 946,000 shares at an average near $9.51 by September 30, 2026.

3. Colorectal and breast cancer trials

The larger long-term question is whether liver-directed melphalan works in more common cancers. A Phase 2 trial in metastatic colorectal cancer with liver involvement, about 90 patients in the third-line setting, compares HEPZATO plus trifluridine-tipiracil and bevacizumab against those two drugs alone. Enrollment began in the third quarter of 2025 and the primary hepatic progression-free survival readout is expected by the end of 2027, with overall survival in 2028. The DELUMA trial in HER2-negative breast cancer with liver-dominant disease dosed its first patient in July 2026 and targets about 90 patients, with a primary readout expected by the end of 2028. Both populations are far larger than uveal melanoma.

4. Pipeline extensions and Europe

Beyond the two Phase 2 trials, Delcath plans an IND submission in cholangiocarcinoma (bile duct cancer) in early 2027 and expects to finish preclinical work on an oxaliplatin-based PHP product by mid-2027, pending FDA agreement. Oxaliplatin is a standard colorectal cancer drug, so a second chemotherapy option could matter more than the melphalan kit in that indication. In Europe, CHEMOSAT revenue was about $2.4 million in the third quarter, up from about $1.3 million a year earlier, helped by a two-year reimbursement approval in Sweden's Vastra Gotaland region in 2025. The CHOPIN trial run by Leiden University Medical Center reported one-year progression-free survival of about 54.7% with PHP plus ipilimumab and nivolumab, versus about 15.8% with PHP alone.

What are the risks to Delcath Systems, Inc. (DCTH)?

Delcath sells essentially one product for one rare cancer. Uveal melanoma affects only a few thousand people a year in the US, and only a portion of them develop liver metastases that fit the HEPZATO label, so the current market has a ceiling. Sales are concentrated: two customers accounted for about 31% of revenue in the first nine months of 2026, and a third for about 6.5%, so a slowdown at one large hospital shows up quickly in the numbers. The fourth quarter of 2025 showed how lumpy volume can be, with a net loss of about $1.9 million after a guidance cut that sent the stock sharply lower. The procedure carries serious side effects, including blood count suppression, and the FDA label includes a boxed warning and a restricted distribution program, which limits how fast new sites can start. Competing systemic drugs, such as Immunocore's Kimmtrak and newer targeted agents in development, could change treatment sequencing. The colorectal and breast trials are randomized Phase 2 studies and may not succeed. Pricing and reimbursement, including 340B discounts and the Medicaid rebate agreement, can pressure realized prices. At about 5.9 times trailing sales and roughly 69 times forward earnings estimates, after a gain of about 89% in 2026, the valuation already assumes continued growth.

What is the Delcath Systems, Inc. (DCTH) forecast?

5 analysts publish price targets on DCTH, averaging $28.60 as of November 2026, or +52.2% against the $18.79 share price on November 20, 2026. The published targets run from $25.00 to $36.00, a moderate spread, and the ratings split 5 buy, 0 hold, 0 sell. Over the last six months there have been 4 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full DCTH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is DCTH a buy or a sell?

We give no verdict on Delcath Systems, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. More treatment centers and more patients per center. HEPZATO sales are a function of active sites and procedure volume. The most optimistic published target, $36.00, assumes this works close to its best case.

The case against. Delcath sells essentially one product for one rare cancer. The most pessimistic target, $25.00, is roughly what DCTH is worth if this bites instead.

Read the full bull and bear case on DCTH, including what would have to change to break either one. Walnut is not an investment adviser.

How is Delcath Systems, Inc. (DCTH) valued?

Market cap, P/E and dividend yield at today's price are in the DCTH key stats above. The business figures below come from Delcath Systems, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$110 million
  • Revenue growth (Q3 2026, year over year): ~70%
  • Net income (TTM): ~$6.7 million
  • Gross margin (Q3 2026): ~89%
  • Cash and investments (no debt): ~$104 million

As of November 2026: At about $18.78 a share (November 20, 2026) and roughly 36 million shares including pre-funded warrants, Delcath is valued near $650 million, or about 5.9 times trailing revenue and roughly 5.0 times after netting out cash. Trailing earnings are small, about $6.7 million once the fourth-quarter 2025 loss is included, so the price-to-earnings ratio is very high and swings with each quarter. Guidance of $115 million to $117 million for 2026 implies fourth-quarter revenue of roughly $26 million to $28 million, below the third quarter's $35.1 million, which suggests management is leaving room for uneven volume. Published analyst targets earlier in 2026 ranged from roughly $19 to $30, and the average of five targets tracked by Yahoo Finance is about $28.60.

Who competes with Delcath Systems, Inc. (DCTH)?

Systemic uveal melanoma drugs

Immunocore's Kimmtrak (tebentafusp) is the main approved systemic therapy for metastatic uveal melanoma, but only for patients with the HLA-A*02:01 tissue type. Bristol Myers Squibb's ipilimumab and nivolumab combination is also used. IDEAYA Biosciences is developing darovasertib combinations. These drugs treat the whole body and compete with HEPZATO for the same patients and the same place in the treatment sequence.

Other liver-directed therapies

Interventional radiologists also treat liver tumors with Y-90 radioembolization, such as Boston Scientific's TheraSphere and Sirtex's SIR-Spheres, plus chemoembolization and ablation. These procedures target individual tumors or liver segments, while HEPZATO treats the whole liver at once. In colorectal and other liver metastases, these established options are the comparison Delcath will face if its trials succeed.

Small-cap oncology device and drug companies

For investors comparing businesses, Delcath trades alongside small and mid-cap oncology companies with one or two commercial products, such as Immunocore (which sells Kimmtrak) and IDEAYA (still clinical stage). These stocks share concentrated revenue, high gross margins and large moves on trial readouts, so site counts, quarterly volume and clinical data drive them more than broad market trends.

What stocks are similar to Delcath Systems, Inc. (DCTH)?

Other names that sit close to DCTH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Delcath Systems, Inc. (DCTH)

There are three common ways to get DCTH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so DCTH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where DCTH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Delcath Systems, Inc. (DCTH)

DCTH is a single-product, profitable rare-cancer device and drug company growing quickly from a small base, where the valuation leans on adding treatment centers and on Phase 2 trials in colorectal and breast cancer.

More on Delcath Systems, Inc. (DCTH)

Whether DCTH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DCTH a buy or a sell?, and where the stock could go from here in the DCTH stock forecast.

For income investors, whether DCTH pays a dividend and how the payout looks is covered in does DCTH pay a dividend? And to weigh DCTH against a peer, read the full side-by-side comparisons: DCTH vs BMY and DCTH vs IDYA.

Wondering how DCTH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Delcath Systems, Inc.

Ask Walnut's AI anything about DCTH and see how it fits what you own.

FAQ

What does Delcath Systems do?

+

Delcath develops and sells percutaneous hepatic perfusion, a procedure that isolates the liver's blood circulation so doctors can deliver a high dose of melphalan chemotherapy directly to liver tumors. Catheters placed through blood vessels carry the drug in, and blood leaving the liver passes through Delcath's filters to remove most of the drug before returning to the rest of the body. In the US the product is called HEPZATO KIT and is approved for uveal melanoma that has spread to the liver and cannot be surgically removed. In Europe the filtration device is sold as CHEMOSAT. The company also runs Phase 2 trials testing the approach in colorectal and breast cancer liver metastases, and plans a bile duct cancer study.

How did Delcath do in the third quarter of 2026?

+

Delcath reported third-quarter 2026 results on November 9, 2026. Revenue was about $35.1 million, up from about $20.6 million a year earlier, made up of about $32.7 million from HEPZATO KIT in the US and about $2.4 million from CHEMOSAT in Europe. Gross margin was about 89%, net income was about $7.0 million or $0.17 per diluted share, and adjusted EBITDA was about $11.5 million. HEPZATO procedure volume grew about 72% from the prior-year quarter, the company had 33 active treatment centers, and operating cash flow was about $8.2 million. Management raised full-year 2026 revenue guidance to $115 million to $117 million and kept a gross margin range of 87% to 89%.

Is Delcath profitable?

+

Yes, on a GAAP basis, though the profits are recent and small. After decades of losses, Delcath reported full-year 2025 net income of about $2.7 million on $85.2 million of revenue, compared with a net loss of about $26.4 million in 2024. The fourth quarter of 2025 was a loss of about $1.9 million, which shows profitability can slip in a slower quarter. In 2026 results improved: nine-month net income was about $8.6 million, or $0.21 per diluted share. Over the trailing twelve months net income is roughly $6.7 million. The company also reports positive adjusted EBITDA and positive operating cash flow, and has no debt.

What is HEPZATO KIT approved for?

+

The FDA approved HEPZATO KIT (melphalan for injection/hepatic delivery system) in August 2023 for adults with uveal melanoma that has spread to the liver, where the liver tumors cannot be removed surgically. The label covers patients whose liver involvement is under 50% of the organ and who have no disease outside the liver, or only limited disease in certain sites such as bone or lymph nodes that can be treated. The approval was based on the FOCUS trial. The drug carries a boxed warning for serious procedural complications and bone marrow suppression, and is available only through a restricted program, which means hospitals must be certified before they can perform the procedure.

How much is Delcath stock worth and how is it valued?

+

On November 20, 2026, DCTH closed near $18.78 a share, giving a market cap of roughly $653 million based on about 34.8 million common shares plus about 1.3 million pre-funded warrants. With about $104 million in cash and short-term investments and no debt, enterprise value is around $550 million. That is about 5.9 times trailing revenue of about $110 million, or about 5.0 times on an enterprise basis. Trailing earnings are small, so the price-to-earnings ratio is high and moves a lot each quarter. Price targets published by analysts earlier in 2026 ranged from roughly $19 to $30, according to MarketBeat in March 2026. The average of five analyst targets tracked by Yahoo Finance in November 2026 was about $28.60.

Why did Delcath stock fall in late 2025?

+

In the fall of 2025 Delcath released preliminary third-quarter results and lowered its full-year revenue outlook, and the stock dropped. The issue was slower HEPZATO procedure volume than the company had planned for, which management tied to uneven patient flow at treatment centers. The fourth quarter of 2025 then came in at about $20.7 million of revenue and a small net loss, and several analysts cut price targets, including Craig-Hallum to $20 from $24 and BTIG to $19 from $23 in February 2026. The shares traded near $8 at their lows. Volume recovered through 2026, with third-quarter HEPZATO revenue of about $32.7 million, and the stock was near $14 in early November before rising to about $18.50 after the third-quarter report and closing near $18.78 on November 20, 2026.

What clinical trials could expand Delcath's market?

+

Delcath is funding two randomized Phase 2 trials. The first enrolls about 90 patients with metastatic colorectal cancer in the third-line setting and compares HEPZATO plus trifluridine-tipiracil and bevacizumab with those two drugs alone. Enrollment started in the third quarter of 2025, with the primary hepatic progression-free survival result expected by the end of 2027. The second, DELUMA, enrolls about 90 patients with HER2-negative breast cancer that is mostly in the liver, with first dosing in July 2026 and a primary readout expected by the end of 2028. The company also plans an IND for cholangiocarcinoma in early 2027 and is developing an oxaliplatin-based version of the PHP system.

What are the biggest risks for DCTH?

+

The main risks are concentration and a small market. Delcath depends on one product approved for one rare cancer, and about 31% of nine-month 2026 revenue came from two customers. Volume can swing from quarter to quarter, as the late 2025 guidance cut showed. The procedure is complex and carries a boxed warning, which slows how fast new hospitals start treating. Systemic drugs such as Kimmtrak, and newer agents in development, compete for the same patients. The colorectal and breast trials could fail, which would leave the company limited to uveal melanoma. Reimbursement terms, including 340B pricing and Medicaid rebates, can affect realized prices. Walnut is not an investment adviser, and this page describes the company, not a course of action.

How has DCTH stock performed in 2026?

+

As of November 20, 2026 DCTH closed near $18.78, up about 89% year to date and about 129% over one year, within a 52-week range of roughly $8.48 to $22.51. The shares are up about 30% over the past month, most of it after the November 9 third-quarter report, which showed revenue of about $35.1 million, net income of $0.17 per share against an expected loss of about $0.08, and raised 2026 revenue guidance of $115 million to $117 million.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Delcath Systems, Inc.'s investor relations page or your broker before making investment decisions.